nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Anthracyclines for gestational breast cancer: course and outcome of pregnancy
|
Azim Jr, H.A. |
|
|
19 |
8 |
p. 1511-1512 |
artikel |
2 |
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
|
Theodore, C. |
|
|
19 |
8 |
p. 1465-1469 |
artikel |
3 |
Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model
|
Tun-Kyi, A. |
|
|
19 |
8 |
p. 1488-1494 |
artikel |
4 |
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
|
Xu, Y. |
|
|
19 |
8 |
p. 1423-1429 |
artikel |
5 |
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
|
Arnold, D. |
|
|
19 |
8 |
p. 1442-1449 |
artikel |
6 |
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
|
Kim, T.M. |
|
|
19 |
8 |
p. 1477-1484 |
artikel |
7 |
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
|
Scionti, I. |
|
|
19 |
8 |
p. 1500-1508 |
artikel |
8 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
|
|
|
|
19 |
8 |
p. 1515 |
artikel |
9 |
Creating a stronger front against cancer: ESMO and ECCO join forces
|
Baselga, José |
|
|
19 |
8 |
p. 1367-1368 |
artikel |
10 |
Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?
|
Necchi, A. |
|
|
19 |
8 |
p. 1509 |
artikel |
11 |
Editorial Board
|
|
|
|
19 |
8 |
p. ii-iii |
artikel |
12 |
Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment
|
Dimeo, F. |
|
|
19 |
8 |
p. 1495-1499 |
artikel |
13 |
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
|
Gruber, G. |
|
|
19 |
8 |
p. 1393-1401 |
artikel |
14 |
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
|
Melichar, B. |
|
|
19 |
8 |
p. 1470-1476 |
artikel |
15 |
Infusion of trastuzumab maintenance doses over 30 minutes
|
Ring, A. |
|
|
19 |
8 |
p. 1509-1510 |
artikel |
16 |
In this issue
|
|
|
|
19 |
8 |
p. 1365 |
artikel |
17 |
Large bowel perforation associated with capecitabine treatment for breast cancer
|
Cowman, S. |
|
|
19 |
8 |
p. 1510-1511 |
artikel |
18 |
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
|
Zoubir, M. |
|
|
19 |
8 |
p. 1402-1406 |
artikel |
19 |
Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
|
Cartron, G. |
|
|
19 |
8 |
p. 1485-1487 |
artikel |
20 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
|
Mrozek, E. |
|
|
19 |
8 |
p. 1417-1422 |
artikel |
21 |
Practical guidance for the management of aromatase inhibitor-associated bone loss
|
Hadji, P. |
|
|
19 |
8 |
p. 1407-1416 |
artikel |
22 |
Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients
|
Jacot, W. |
|
|
19 |
8 |
p. 1458-1464 |
artikel |
23 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
|
Dank, M. |
|
|
19 |
8 |
p. 1450-1457 |
artikel |
24 |
Satisfaction with and psychological impact of immediate and deferred breast reconstruction
|
Fernández-Delgado, J. |
|
|
19 |
8 |
p. 1430-1434 |
artikel |
25 |
Stopping a trial early in oncology: for patients or for industry?
|
Whitehead, J. |
|
|
19 |
8 |
p. 1512-1513 |
artikel |
26 |
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor
|
de La Motte Rouge, T. |
|
|
19 |
8 |
p. 1435-1441 |
artikel |
27 |
Table of Contents
|
|
|
|
19 |
8 |
p. iv-v |
artikel |
28 |
Targeting Src in breast cancer
|
Finn, R.S. |
|
|
19 |
8 |
p. 1379-1386 |
artikel |
29 |
Temsirolimus in metastatic renal cell carcinoma
|
Négrier, S. |
|
|
19 |
8 |
p. 1369-1370 |
artikel |
30 |
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
|
Bellmunt, J. |
|
|
19 |
8 |
p. 1387-1392 |
artikel |
31 |
UFT (tegafur–uracil) in rectal cancer
|
Casado, E. |
|
|
19 |
8 |
p. 1371-1378 |
artikel |
32 |
Value of frontline autologous stem-cell transplantation in peripheral T-cell lymphoma
|
Gutierrez, A. |
|
|
19 |
8 |
p. 1512 |
artikel |